Concord Biotech, 543960, CONCORDBIO Share Price, Rating, Research, Analysis, Fundamental & Historical Data

Stock Summary

Market Cap(Crs)
Stock P:E
Face Value

17,129.33
48.10
1

Enterprise Value(Crs)
Dividend Yield
Price:Book Value

17,128.53
0.65%
9.23

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

10 Years
5 Years
3 Years

15.83
14.23
12.05

EBITDA CAGR (%)

10 Years
5 Years
3 Years

14.10
9.10
7.77

PAT CAGR (%)

10 Years
5 Years
3 Years

15.64
9.57
15.68

P:E (Median)

8 Years
5 Years
3 Years

P:BV (Average)

8 Years
5 Years
3 Years

EV:EBITDA (Average)

8 Years
5 Years
3 Years

Earnings Forecasts:

(Updated: 06-06-2025)

Description 2024 2025 2026 2027
Adj EPS 29.45 35.52 41.66 51.31
P/E Ratio 55.77 46.24 39.43 32.01
Revenue 998 1200 1398 1672
EBITDA 432 582 709
Net Income 308 372 436 536
ROA 19.2 21 22
P/B Ratio 11.27 7.88 6.54
ROE 21.88 20.85 20.9
FCFF 180 314 616
FCFF Yield 1.07 1.86 3.66
Net Debt -281 -668 -908
BVPS 145.8 208.43 251.13

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 203.99 215.80 -5.47% 429.88 318.97 34.77% 244.22 240.80 1.42% 310.18 262.35 18.23%
Expenses 142.59 134.52 6.00% 239.46 184.68 29.66% 146.27 134.87 8.45% 173.50 143.16 21.19%
EBITDA 61.40 81.28 -24.46% 190.42 134.29 41.80% 97.95 105.93 -7.53% 136.68 119.19 14.67%
EBIDTM 30.10% 37.66% 44.30% 42.10% 40.11% 43.99% 44.06% 45.43%
Other Income 13.68 10.31 32.69% 9.38 10.81 -13.23% 14.73 8.19 79.85% 10.03 8.13 23.37%
Interest 0.06 0.24 -75.00% 0.10 0.46 -78.26% 0.10 0.50 -80.00% 0.10 0.84 -88.10%
Depreciation 17.78 13.18 34.90% 14.62 13.72 6.56% 13.26 13.54 -2.07% 13.31 13.29 0.15%
PBT 57.24 78.17 -26.77% 185.09 130.92 41.38% 99.32 100.09 -0.77% 133.29 113.18 17.77%
Tax 14.67 19.93 -26.39% 43.16 33.70 28.07% 25.23 25.53 -1.18% 34.59 28.69 20.56%
PAT 42.57 58.24 -26.91% 141.94 97.21 46.01% 74.09 74.55 -0.62% 98.70 84.49 16.82%
PATM 20.87% 26.99% 33.02% 30.48% 30.34% 30.96% 31.82% 32.21%
EPS 4.07 5.57 -26.93% 13.57 9.29 46.07% 7.08 7.13 -0.70% 9.44 8.08 16.83%

Description Jun 25 Jun 24 Var% Mar 25 Mar 24 Var% Dec 24 Dec 23 Var% Sep 24 Sep 23 Var%
Net Sales 203.99 215.80 -5.47% 429.88 318.97 34.77% 244.22 240.80 1.42% 310.18 262.35 18.23%
Expenses 142.59 134.52 6.00% 239.46 184.68 29.66% 146.27 134.87 8.45% 173.50 143.16 21.19%
EBITDA 61.40 81.28 -24.46% 190.42 134.29 41.80% 97.95 105.93 -7.53% 136.68 119.19 14.67%
EBIDTM 30.10% 37.66% 44.30% 42.10% 40.11% 43.99% 44.06% 45.43%
Other Income 13.68 10.31 32.69% 9.38 10.81 -13.23% 14.73 8.19 79.85% 10.03 8.13 23.37%
Interest 0.06 0.24 -75.00% 0.10 0.46 -78.26% 0.10 0.50 -80.00% 0.10 0.84 -88.10%
Depreciation 17.78 13.18 34.90% 14.62 13.72 6.56% 13.26 13.54 -2.07% 13.31 13.29 0.15%
PBT 57.24 78.17 -26.77% 185.09 130.92 41.38% 99.32 100.09 -0.77% 133.29 113.18 17.77%
Tax 14.67 19.93 -26.39% 43.16 33.70 28.07% 25.23 25.53 -1.18% 34.59 28.69 20.56%
PAT 42.57 58.24 -26.91% 141.94 97.21 46.01% 74.09 74.55 -0.62% 98.70 84.49 16.82%
PATM 20.87% 26.99% 33.02% 30.48% 30.34% 30.96% 31.82% 32.21%
EPS 4.21 5.70 -26.14% 13.42 9.08 47.80% 7.26 7.41 -2.02% 9.15 7.74 18.22%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 16 Mar 15 Mar 14 Mar 13 Mar 12
Net Sales 1,188.27 1,200.09 1,016.94 853.17 712.93 616.94 276.17 238.53 204.82 164.91 135.60 Net Sales Growth 14.49% 18.01% 19.20% 19.67% 15.56% 123.39% 15.78% 16.46% 24.20% 21.62% Cost Of Goods Sold 302.31 305.51 229.20 180.21 164.01 111.56 63.26 54.22 48.88 34.30 25.07 Gross Profit 885.96 894.57 787.74 672.96 548.92 505.37 212.91 184.31 155.93 130.61 110.53 GP Margin 74.56% 74.54% 77.46% 78.88% 76.99% 81.92% 77.09% 77.27% 76.13% 79.20% 81.51% Total Expenditure 701.82 693.24 584.75 504.59 439.01 289.01 140.63 127.67 119.26 88.75 69.85 Power & Fuel Cost - 112.23 104.97 97.65 71.64 39.86 26.89 28.90 29.45 25.71 21.27 % Of Sales - 9.35% 10.32% 11.45% 10.05% 6.46% 9.74% 12.12% 14.38% 15.59% 15.69% Employee Cost - 138.93 123.05 110.28 95.69 69.47 22.87 19.78 15.57 13.44 10.88 % Of Sales - 11.58% 12.10% 12.93% 13.42% 11.26% 8.28% 8.29% 7.60% 8.15% 8.02% Manufacturing Exp. - 38.74 37.39 38.44 32.45 21.97 12.42 12.32 12.35 8.45 7.00 % Of Sales - 3.23% 3.68% 4.51% 4.55% 3.56% 4.50% 5.16% 6.03% 5.12% 5.16% General & Admin Exp. - 52.19 48.57 45.72 31.09 22.52 8.72 6.53 6.42 3.54 2.59 % Of Sales - 4.35% 4.78% 5.36% 4.36% 3.65% 3.16% 2.74% 3.13% 2.15% 1.91% Selling & Distn. Exp. - 34.55 33.11 23.70 21.44 13.36 4.80 4.40 3.68 2.00 1.44 % Of Sales - 2.88% 3.26% 2.78% 3.01% 2.17% 1.74% 1.84% 1.80% 1.21% 1.06% Miscellaneous Exp. - 11.09 8.46 8.59 22.69 10.26 1.67 1.52 2.90 1.31 1.44 % Of Sales - 0.92% 0.83% 1.01% 3.18% 1.66% 0.60% 0.64% 1.42% 0.79% 1.17% EBITDA 486.45 506.85 432.19 348.58 273.92 327.93 135.54 110.86 85.56 76.16 65.75 EBITDA Margin 40.94% 42.23% 42.50% 40.86% 38.42% 53.15% 49.08% 46.48% 41.77% 46.18% 48.49% Other Income 47.82 44.45 33.78 35.31 23.42 13.81 4.58 5.51 2.83 5.31 2.58 Interest 0.36 1.04 3.18 9.80 6.13 1.05 0.32 0.82 0.70 0.30 0.41 Depreciation 58.97 54.37 53.59 54.03 50.05 27.52 10.46 9.67 11.43 10.14 8.97 PBT 474.94 495.88 409.19 320.05 241.16 313.17 129.34 105.88 76.25 71.04 58.95 Tax 117.65 122.91 104.46 81.93 62.59 77.83 42.09 35.63 21.83 21.65 17.17 Tax Rate 24.77% 24.79% 25.53% 25.60% 25.95% 24.85% 32.54% 33.65% 28.63% 30.48% 29.13% PAT 357.30 372.96 304.73 238.13 178.57 235.33 87.25 70.25 54.41 49.39 41.78 PAT before Minority Interest 357.30 372.96 304.73 238.13 178.57 235.33 87.25 70.25 54.41 49.39 41.78 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 30.07% 31.08% 29.97% 27.91% 25.05% 38.14% 31.59% 29.45% 26.56% 29.95% 30.81% PAT Growth 13.61% 22.39% 27.97% 33.35% -24.12% 169.72% 24.20% 29.11% 10.16% 18.21% EPS 34.16 35.66 29.13 22.77 17.07 22.50 8.34 6.72 5.20 4.72 3.99

Description TTM Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Net Sales 1,188.27 1,200.09 1,016.94 853.17 712.93 616.94 Net Sales Growth 14.49% 18.01% 19.20% 19.67% 15.56% Cost Of Goods Sold 302.31 305.51 229.20 180.21 164.01 111.56 Gross Profit 885.96 894.57 787.74 672.96 548.92 505.38 GP Margin 74.56% 74.54% 77.46% 78.88% 76.99% 81.92% Total Expenditure 701.82 693.24 584.75 504.59 439.01 289.01 Power & Fuel Cost - 112.23 104.97 97.65 71.64 39.86 % Of Sales - 9.35% 10.32% 11.45% 10.05% 6.46% Employee Cost - 138.93 123.05 110.28 95.69 69.47 % Of Sales - 11.58% 12.10% 12.93% 13.42% 11.26% Manufacturing Exp. - 38.74 37.39 38.44 32.48 21.97 % Of Sales - 3.23% 3.68% 4.51% 4.56% 3.56% General & Admin Exp. - 52.19 48.57 45.72 31.09 22.52 % Of Sales - 4.35% 4.78% 5.36% 4.36% 3.65% Selling & Distn. Exp. - 34.55 33.11 23.70 21.44 13.36 % Of Sales - 2.88% 3.26% 2.78% 3.01% 2.17% Miscellaneous Exp. - 11.09 8.46 8.59 22.66 10.26 % Of Sales - 0.92% 0.83% 1.01% 3.18% 1.66% EBITDA 486.45 506.85 432.19 348.58 273.92 327.93 EBITDA Margin 40.94% 42.23% 42.50% 40.86% 38.42% 53.15% Other Income 47.82 44.45 33.78 35.31 23.42 13.81 Interest 0.36 1.04 3.18 9.80 6.13 1.05 Depreciation 58.97 54.37 53.59 54.03 50.05 27.52 PBT 474.94 495.88 409.19 320.05 241.16 313.17 Tax 117.65 122.91 104.46 81.93 62.59 77.83 Tax Rate 24.77% 24.79% 25.53% 25.60% 25.95% 24.85% PAT 357.30 371.64 308.10 240.09 174.93 235.34 PAT before Minority Interest 357.30 371.64 308.10 240.09 174.93 235.34 Minority Interest 0.00 0.00 0.00 0.00 0.00 0.00 PAT Margin 30.07% 30.97% 30.30% 28.14% 24.54% 38.15% PAT Growth 13.61% 20.62% 28.33% 37.25% -25.67% EPS 34.16 35.53 29.46 22.95 16.72 22.50

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10
Shareholder's Funds 1,812.65 1,525.25 1,291.98 1,107.16 999.67 226.47 185.52 146.30 111.20 77.28 Share Capital 10.46 10.46 10.46 9.51 9.51 9.21 4.60 4.60 4.60 2.30 Total Reserves 1,802.18 1,514.79 1,281.52 1,097.65 990.16 217.26 180.92 141.69 106.60 74.98 Non-Current Liabilities 37.47 31.91 32.13 54.40 77.43 10.53 9.03 7.94 7.97 5.90 Secured Loans 0.00 0.00 6.24 31.25 56.25 0.00 0.00 0.00 0.00 2.27 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 2.82 1.96 2.30 1.87 2.10 0.27 0.28 0.55 0.78 0.00 Current Liabilities 184.06 142.16 190.53 340.97 235.93 37.96 27.55 24.26 21.01 16.30 Trade Payables 113.04 94.44 93.80 83.11 46.40 15.38 9.03 6.95 5.22 8.35 Other Current Liabilities 54.97 38.32 60.26 62.70 53.58 3.93 2.28 3.58 6.45 1.54 Short Term Borrowings 0.38 0.00 0.00 4.34 5.10 4.97 3.62 6.59 3.86 0.00 Short Term Provisions 15.67 9.40 36.47 190.82 130.85 13.68 12.62 7.15 5.47 6.41 Total Liabilities 2,034.18 1,699.32 1,514.64 1,502.53 1,313.03 274.96 222.10 178.50 140.18 99.48 Net Block 794.69 575.32 592.98 572.98 546.22 98.73 81.62 69.48 63.94 40.42 Gross Block 1,097.16 828.31 792.80 718.85 644.29 161.05 132.77 110.61 96.21 65.56 Accumulated Depreciation 302.48 253.00 199.81 145.87 98.08 62.31 51.15 41.14 32.28 25.14 Non Current Assets 898.94 803.08 786.95 869.87 705.89 113.02 88.35 87.86 73.36 52.46 Capital Work in Progress 50.66 211.48 172.70 74.16 17.95 8.02 3.97 14.42 7.00 12.04 Non Current Investment 18.65 0.67 0.79 0.92 0.67 0.56 0.56 0.00 0.00 0.00 Long Term Loans & Adv. 12.01 12.81 11.61 220.99 140.61 5.72 2.00 3.77 2.41 0.00 Other Non Current Assets 22.93 2.81 8.87 0.82 0.45 0.00 0.21 0.19 0.00 0.00 Current Assets 1,135.24 896.23 727.70 632.67 607.15 161.94 133.75 90.64 66.81 47.03 Current Investments 316.54 243.70 136.93 73.47 140.99 0.00 2.00 2.02 0.00 3.01 Inventories 239.67 207.95 212.31 195.12 153.61 39.41 34.36 23.66 18.75 14.04 Sundry Debtors 521.65 349.61 273.76 232.17 177.52 100.35 85.43 54.83 30.17 23.82 Cash & Bank 1.18 47.02 43.45 88.93 60.82 2.67 1.53 1.04 12.22 0.61 Other Current Assets 56.19 26.82 45.57 32.53 74.22 19.50 10.42 9.09 5.67 5.54 Short Term Loans & Adv. 27.40 21.12 15.68 10.44 33.85 10.58 2.76 2.83 2.07 5.34 Net Current Assets 951.18 754.08 537.17 291.70 371.22 123.98 106.20 66.38 45.81 30.73 Total Assets 2,034.18 1,699.31 1,514.65 1,502.54 1,313.04 274.96 222.10 178.50 140.17 99.49

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Shareholder's Funds 1,812.72 1,526.65 1,290.00 1,103.22 999.37 Share Capital 10.46 10.46 10.46 9.51 9.51 Total Reserves 1,802.26 1,516.18 1,279.54 1,093.71 989.86 Non-Current Liabilities 37.47 31.91 32.13 54.40 77.43 Secured Loans 0.00 0.00 6.24 31.25 56.25 Unsecured Loans 0.00 0.00 0.00 0.00 0.00 Long Term Provisions 2.82 1.96 2.30 1.87 2.10 Current Liabilities 184.06 142.16 191.84 344.24 235.93 Trade Payables 113.04 94.44 93.80 83.11 46.40 Other Current Liabilities 54.97 38.32 61.57 65.98 53.58 Short Term Borrowings 0.38 0.00 0.00 4.34 5.10 Short Term Provisions 15.67 9.40 36.47 190.82 130.85 Total Liabilities 2,034.25 1,700.72 1,513.97 1,501.86 1,312.73 Net Block 794.69 575.32 592.98 572.98 546.22 Gross Block 1,097.16 828.31 792.80 718.85 645.33 Accumulated Depreciation 302.48 253.00 199.81 145.87 99.11 Non Current Assets 899.01 804.48 786.28 869.20 705.59 Capital Work in Progress 50.66 211.48 172.70 74.16 17.95 Non Current Investment 18.73 2.06 0.12 0.26 0.37 Long Term Loans & Adv. 12.01 12.81 11.61 220.99 140.61 Other Non Current Assets 22.93 2.81 8.87 0.82 0.45 Current Assets 1,135.24 896.23 727.70 632.67 607.15 Current Investments 316.54 243.70 136.93 73.47 140.99 Inventories 239.67 207.95 212.31 195.12 153.61 Sundry Debtors 521.65 349.61 273.76 232.17 177.52 Cash & Bank 1.18 47.02 43.45 88.93 60.82 Other Current Assets 56.19 26.82 45.57 32.53 74.22 Short Term Loans & Adv. 27.40 21.12 15.68 10.44 33.85 Net Current Assets 951.18 754.08 535.86 288.42 371.22 Total Assets 2,034.25 1,700.71 1,513.98 1,501.87 1,312.74

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10
Cash From Operating Activity 244.52 265.47 246.00 207.47 166.81 39.81 21.53 16.14 36.04 34.70 PBT 495.88 409.19 320.05 241.16 313.17 76.25 71.04 58.95 55.28 55.92 Adjustment 28.82 40.80 48.51 49.16 17.59 15.07 8.58 8.18 7.52 5.26 Changes in Working Capital -170.76 -81.18 -52.29 -22.06 -88.77 -24.01 -41.68 -33.34 -11.66 -9.66 Cash after chg. in Working capital 353.94 368.82 316.28 268.26 241.99 67.30 37.94 33.79 51.14 51.53 Interest Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Tax Paid -109.42 -103.35 -70.28 -60.78 -75.18 -27.49 -16.41 -17.64 -15.10 -16.82 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -159.99 -154.61 -157.95 -111.79 -195.20 -31.41 -10.85 -21.79 -22.40 -8.71 Net Fixed Assets -108.03 -74.29 -172.49 -130.77 -493.17 -32.33 -11.71 -21.82 -25.61 -18.18 Net Investments -90.82 -106.65 -63.33 67.27 -141.10 2.00 -0.54 -2.02 3.01 9.02 Others 38.86 26.33 77.87 -48.29 439.07 -1.08 1.40 2.05 0.20 0.45 Cash from Financing Activity -98.77 -99.21 -85.22 -100.16 31.12 -9.32 -9.82 -3.83 -1.98 -25.61 Net Cash Inflow / Outflow -14.24 11.64 2.83 -4.48 2.74 -0.91 0.85 -9.48 11.66 0.38 Opening Cash & Equivalents 15.14 3.50 0.67 5.14 2.41 3.52 2.66 12.14 0.57 0.23 Closing Cash & Equivalent 0.90 15.14 3.50 0.67 5.14 2.60 3.52 2.66 12.22 0.61

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Cash From Operating Activity 244.52 265.47 246.00 207.47 166.82 PBT 494.55 412.56 322.01 237.52 312.72 Adjustment 30.14 37.43 46.55 52.80 18.04 Changes in Working Capital -170.76 -81.18 -52.29 -22.05 -88.76 Cash after chg. in Working capital 353.94 368.82 316.28 268.26 241.99 Interest Paid 0.00 0.00 0.00 0.00 0.00 Tax Paid -109.42 -103.35 -70.28 -60.78 -75.18 Other Direct Exp. Paid 0.00 0.00 0.00 0.00 0.00 Extra & Other Items 0.00 0.00 0.00 0.00 0.00 Cash From Investing Activity -159.99 -154.61 -157.95 -111.79 -195.21 Net Fixed Assets -108.03 -74.29 -172.49 -130.77 Net Investments -90.82 -106.65 -63.33 67.27 Others 38.86 26.33 77.87 -48.29 Cash from Financing Activity -98.77 -99.21 -85.22 -100.16 31.12 Net Cash Inflow / Outflow -14.24 11.64 2.83 -4.48 2.74 Opening Cash & Equivalents 15.14 3.50 0.67 5.14 2.41 Closing Cash & Equivalent 0.90 15.14 3.50 0.67 5.14

Financial Ratios

Standalone /

Consolidated

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21 Mar 14 Mar 13 Mar 12 Mar 11 Mar 10
Book Value (Rs.) 173.27 145.80 123.50 105.83 95.56 246.02 403.07 317.85 241.60 335.83 ROA 19.98% 18.96% 15.78% 12.68% 20.89% 21.89% 24.66% 26.22% 32.78% 38.53% ROE 22.35% 21.63% 19.85% 16.95% 26.60% 26.42% 29.77% 32.45% 41.68% 51.67% ROCE 29.72% 28.89% 26.48% 21.94% 33.00% 36.59% 41.71% 44.18% 56.95% 74.38% Fixed Asset Turnover 1.25 1.25 1.13 1.05 1.29 1.44 1.42 1.35 1.39 1.79 Receivable days 132.49 111.87 108.22 104.87 106.80 160.03 148.42 111.49 87.54 59.62 Inventory Days 68.07 75.42 87.15 89.27 78.34 63.55 61.40 55.63 53.17 49.83 Payable days 123.94 149.88 179.16 144.10 192.42 36.90 30.92 29.60 45.56 48.65 Cash Conversion Cycle 76.63 37.41 16.22 50.04 -7.28 186.68 178.90 137.51 95.15 60.81 Total Debt/Equity 0.00 0.00 0.02 0.05 0.09 0.02 0.02 0.05 0.04 0.03 Interest Cover 477.03 129.52 33.65 40.31 300.20 109.58 238.74 144.64 156.79 119.05

Description Mar 25 Mar 24 Mar 23 Mar 22 Mar 21
Book Value (Rs.) 173.27 145.93 123.31 105.45 95.52 ROA 19.90% 19.17% 15.92% 12.43% 20.89% ROE 22.26% 21.88% 20.06% 16.64% 26.60% ROCE 29.62% 29.13% 26.70% 21.66% 33.01% Fixed Asset Turnover 1.25 1.25 1.13 1.05 1.29 Receivable days 132.49 111.87 108.22 104.87 106.80 Inventory Days 68.07 75.42 87.15 89.27 78.34 Payable days 123.94 149.88 179.16 144.10 192.42 Cash Conversion Cycle 76.63 37.41 16.22 50.04 -7.28 Total Debt/Equity 0.00 0.00 0.02 0.05 0.09 Interest Cover 475.76 130.57 33.85 39.72 300.11

Top Investors:

aryavir jhunjhunwala discretionary trust

nishtha jhunjhunwaladiscretionary trust

aryaman jhunjhunwaladiscretionary trust

government pension fund global

1575773 ontario inc

amal parikh

tata aia life insurance co ltd unit linked multi cap fund

axis max life insurance limited a/c reversionary bonus participating - equity

ravindra raichand dharamshi

chanakya corporate services private limited

Annual Reports:

News Update:

Concord Biotech completes Russian GMP inspection
28th Jul 2025, 15:00 PM

The inspection was conducted at company's Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat
Read More
Concord Biotech incorporates wholly owned subsidiary
23rd Jul 2025, 12:30 PM

The newly incorporated entity belongs to Biopharmaceutical Industry
Read More
Concord Biotech makes equity investment of $1,500 in Stellon Biotech Inc
2nd Jul 2025, 14:12 PM

The company proposed to utilize this U.S. Subsidiary to distribute and sell its products in USA
Read More
Concord Biotech gets EIR from USFDA for API facility at Dholka
24th Jun 2025, 15:43 PM

The said inspection was conducted from April 28, 2025 till May 02, 2025
Read More

Concord Biotech Ltd.

Pharmaceuticals & Drugs

BSE: 543960 | NSE: CONCORDBIO

Stock Summary

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update:

Concord Biotech Ltd.

Pharmaceuticals & Drugs

BSE: 543960 | NSE: CONCORDBIO

Stock Summary

Shareholding Pattern

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

EBITDA CAGR (%)

PAT CAGR (%)

P:E (Median)

P:BV (Average)

EV:EBITDA (Average)

Earnings Forecasts:

Quarterly Results

Consolidated Figures in Rs. Crores /

Annual Results

Standalone Figures in Rs. Crores /

Results Balance Sheet

Standalone Figures in Rs. Crores /

Cash Flow

Standalone Figures in Rs. Crores /

Financial Ratios

Standalone /

Top Investors:

Annual Reports:

News Update: